India has no booster plan yet as natural infection rate high: Report



India is not considering authorising booster COVID-19 doses yet as many in the country have been naturally infected and the government believes two doses of a vaccine offers sufficient protection for now, three sources with knowledge of the matter said.


As vaccine supplies have increased, some doctors and public health experts in India have urged the government to start a booster programme for the most vulnerable like many Western nations have done.





But authorities will instead concentrate on having most of India’s 944 million adults complete a two-dose vaccination by January before shifting their focus to a big expansion in exports, said the sources who are involved in vaccine-policy discussions.


So far, 81% of India’s adults have received at least one dose while 43% have had two doses. Vaccination for people under 18 has not yet begun.


“The priority is to fully immunise the adult population,” said one of the sources. The sources declined to be named as the matter was still being discussed by policy makers.


“A big majority has been naturally infected, and for them two doses are enough. That’s why we are seeing that even after recent festivals, cases are not rising.” The source said that once most adults have had two vaccine doses, the government could make boosters optional.


The health ministry did not respond to a request for comment.


India reported the most COVID-19 case and death figures in the world in April and May and government surveys have shown that nearly 70% of Indians were naturally infected by July. The country has so far logged 34.5 million infections – the most after the United States – with more than 465,000 deaths.


Although India celebrated two of its biggest festivals, Diwali and Durga Puja in October and November, infections have fallen to multi-month lows.


Many Western countries are expanding their booster programmes, even for people without compromised immunity – a policy which the World Health Organization has heavily criticised.


Indian vaccine companies like the Serum Institute of India, which produces licensed versions of the AstraZeneca and Novavax shots, expect the government to allow boosters some time early next year.


Dr. Reddy’s Laboratories says it is in talks with India’s drug regulator to sell Russia’s Sputnik Light as a booster dose.


Indian states had more than 216 million vaccine doses in stock as of early Monday.


India’s vaccine output has more than tripled since April to around 300 million doses a month.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor